AZNNEUTRAL

AZN P/E Ratio Analysis

27.0x

Higher than 38% of Healthcare sector peers

Updated 1643h ago·SEC filings & market data

Key Takeaway

AstraZeneca’s current P/E ratio of 27.0x means investors are paying $27.00 for every $1.00 of the company’s earnings per share — a common valuation measure that compares stock price to profitability.

Sector Performance

38th percentile

AZN

27.0x

Sector Median

28.5x

Sector Avg

35.3x

Prior Period

28.0x(May 2026)

↑ Improving

📊

Deep Analysis

This sits above the sector median of 24.6x, placing the stock at the 59th percentile among healthcare peers, indicating a slightly higher valuation than most. No historical trend data is available: the year-over-year change, quarter-over-quarter change, and eight-quarter trend direction are all listed as N/A. The absence of any trend information means investors cannot assess whether the P/E is rising or falling, leaving the current level as the only signal. A valuation above the sector median without trend context introduces no clear risk or opportunity — the stock is priced above average, but without momentum data, the implication is neutral. This metric supports the overall NEUTRAL verdict: the P/E is neither extremely expensive nor cheap, and the lack of trend removes any directional bias.

Frequently Asked Questions

What does the P/E Ratio tell investors about AZN?

Measures how much investors pay per dollar of earnings. A high P/E signals growth expectations; a low P/E may indicate undervaluation or slow growth.

How is the P/E Ratio calculated?

P/E Ratio is calculated as: Price / EPS.

How does AZN's P/E Ratio compare to its sector?

AZN's P/E Ratio of 27.0x compares to a Healthcare sector median of 28.5x, placing it in the 38th percentile.

Who are AZN's closest peers by P/E Ratio?

The closest Healthcare peers by P/E Ratio include: ABT (28.5x), CCLD (28.3x), ALGN (29.1x), AMGN (24.7x), CAH (32.8x).

📚

Learn More About P/E Ratio

DCF Valuation: How to Estimate What a Stock Is Actually Worth

Discounted Cash Flow is the most rigorous way to value a company. It's also the most misunderstood. Here's a plain-English walkthrough with a real example.

The Formula

Price / EPS

Why It Matters

Measures how much investors pay per dollar of earnings. A high P/E signals growth expectations; a low P/E may indicate undervaluation or slow growth.